Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020.
Business Wire · 14h ago
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 6d ago
Ocular Therapeutix Rises 7% On Stellar Results Backed By Dextenza
Shares of Ocular Therapeutix rose 7% on Nov. 6 after the biopharma reported better-than-expected third quarter results driven by the demand for Dextenza, a corticosteroid that treats ocular inflammation and pain following ophthalmic surgery.Ocular Therapeutix’s (OCUL) 3Q revenue increased 609% year-over-year to $5.88 million and exceeded analysts’ consensus by $0.02 million. The top-line gained from higher Dextenza revenue driven by the continued re-opening of Ambulatory Surgery Centers (or ASCs) and Hospital Outpatient Departments (or HOPDs).The company also attributed the increase in Dextenza revenue to the “impact of the DEXTENZA rebate program and the more recent physician payment of the procedure CPT code 0356T by some of the MACs [Medicare Administrative Contractors].”Meanwhile, Ocular posted a net loss per share of $0.21 in 3Q20 down from a net loss per share of $0.45 in 3Q19. Ocular fared better than analysts’ forecast of a loss per share of $0.23Ocular CEO Antony Mattessich commented “DEXTENZA’s momentum continues as a result of key initiatives implemented earlier in the year and exemplified by a robust 280% increase over the prior quarter. This momentum has continued into the fourth quarter with nearly 4,200 billable inserts sold to ASCs and HOPDs in the month of October.”“Within our pipeline, we have four clinical-stage programs that are each highly differentiated ophthalmology specialty products in markets where current annual global sales are estimated to exceed $20 billion,” added the CEO.“With an improved cash position following the completion of a successful financing in October and the recently concluded license agreement with AffaMed Therapeutics, we believe we are now in a position to fund each of these four planned programs through its respective read-out of Phase 2 clinical trial data to capture the full potential benefit of the Phase 2 value inflection.” (See OCUL stock analysis on TipRanks)Following the earnings release and pipeline update, Piper Sandler analyst Joseph Catanzaro increased his price target for Ocular Therapeutix to $16 from $14 and reiterated a Buy rating.In a research note to investors, the analyst also noted that the company's next week's OTX-TKi (chronic treatment of dry eye disease) update will include updated data from cohorts 1 and 2, which is likely to be "incremental" but will still provide "important insight" around durability and long-term tolerability of the program.With shares advancing a whopping 226% year-to-date, the average analyst price target of $15.25 indicates upside potential of about 19% in the coming months. Ocular scores a Strong Buy analyst consensus based on 4 unanimous Buys.Related News: AIG Mulls IPO Or 19.9% Stake Sale Of Life, Retirement Unit; Wells Fargo Raises PT AstraZeneca’s Heart Drug Gets FDA Nod For Stroke Reduction Use Hologic Quarterly Profit Triples On Covid-19 Test Sales; Shares Rise More recent articles from Smarter Analyst: * Domtar Surprises With 3Q Profit; KeyBanc Sticks To Hold * Pfizer, BioNTech Announce COVID-19 Vaccine is 90% Effective; Shares Pop in Pre-Market Trading * Mylan's 3Q Profit Misses The Street; Cowen Sticks To Hold * Canada’s Canopy Growth Pops 12% On Blowout Quarter, Cost Cuts
SmarterAnalyst · 11/09 11:18
Ocular Therapeutics +9.2% Q3 smasher, revenue surges on drug used for ocular inflammation and pain
Ocular Therapeutics ([[OCUL]] +9.0%) reports Q3 total net product revenue of $5.88M vs. $1.6M in Q2, beats consensus by $0.02M.DEXTENZA net product revenue was $5.4M, a 280% increase Q/Q.R&D expenses were
Seekingalpha · 11/06 17:04
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 8.70% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/05 22:35
Ocular Therapeutix Q3 EPS $(0.21) Beats $(0.24) Estimate, Sales $5.90M Beat $5.49M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is a 53.33 percent increase over losses of $(0.45) per share from
Benzinga · 11/05 21:15
Ocular Therapeutix EPS beats by $0.02, beats on revenue
Ocular Therapeutix (OCUL): Q3 GAAP EPS of -$0.21 beats by $0.02.Revenue of $5.88M (+608.4% Y/Y) beats by $0.02M.Press Release
Seekingalpha · 11/05 21:02
Ocular Therapeutix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Ocular Therapeutix, Inc.
ACCESSWIRE · 11/05 19:30
Ocular nabs permanent U.S. reimbursement code for Dextenza
Ocular Therapeutix (OCUL) announces that its application for a permanent Category I CPT reimburse code for the administration of drug-eluting intracanalicular inserts, including Dextenza (dexamethasone ophthalmic insert) 0.4 mg, has
Seekingalpha · 11/04 13:10
Ocular Therapeutix Reports Receipt Of Permanent Category I CPT Code From American Medical Association For Insertion Of Intracanalicular Inserts
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that its
Benzinga · 11/04 13:01
Ocular Therapeutix inks distribution deal in Asia valued up to $103M
Ocular Therapeutics (OCUL) announces a license agreement and collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza (dexamethasone ophthalmic insert) 0.4 mg and pipeline candidate OTX-TIC (travoprost implant)
Seekingalpha · 10/30 12:42
Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced a license
Benzinga · 10/30 12:03
Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 10/29 17:24
Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Ocular Therapeutix (OCUL).
Zacks · 10/22 12:32
Sorrento Therapeutics, Ocular Therapeutix among major healthcare premarket losers' pack
Cyclerion Therapeutics (CYCN) -41% after Phase 2 STRONG-SCD study results in patients with Sickle Cell Disease.Sorrento Therapeutics (SRNE) -12%.Aethlon Medical (AEMD) -11%.Enzo Biochem ENZ -10% on FQ4 earnings results.Auris Medical Holding (EARS) -10%.SOS (SOS) -10%.Ocular Therapeutix
Seekingalpha · 10/14 12:20
Ocular Therapeutix under pressure on pricing ~$70M equity offering
Ocular Therapeutix (OCUL) has priced public offering of 7.18M common stock at $9.75/share, for gross proceeds of ~$70M.Underwriters' over-allotment is an additional 1.08M shares.Closing date is October 16, 2020.Also read
Seekingalpha · 10/14 10:35
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 7,180,000 shares of its common stock at a public offering price of $9.75 per share for gross proceeds of approximately $70 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,077,000 shares in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about October 16, 2020, subject to the satisfaction of customary closing conditions.
Business Wire · 10/14 10:30
Ocular Therapeutix reaches agreement with FDA to conduct retrospective study for ReSure sealant
In an 8-K filing, Ocular Therapeutix (OCUL) provides an update on a previously-disclosed close-out letter from the FDA in connection with a post-approval study for its ReSure Sealant product.Such warning
Seekingalpha · 10/14 09:26
Ocular Therapeutix Announces Proposed Public Offering of Common Stock
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of its common stock.
Business Wire · 10/13 22:01
MDRX, VOXX, ENZ and FLWS among after-hours movers
Gainers: [[MDRX]] +49.2%. [[VOXX]] +18.1%. [[BBBY]] +6.2%. [[FUBO]] +5.6%. [[GME]] +5.6%.Losers: [[ENZ]] -10.7%. [[ATEC]] -9.2%. [[OCUL]] -9.2%. [[PNTG]] -6.1%. [[FLWS]] -4.7%.
Seekingalpha · 10/13 21:42
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular through multiple platforms. This information may help you make smarter investment decisions.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.More